journal article·2022-12-31Open access

MicroRNA-219 loaded chitosan nanoparticles for treatment of glioblastoma

Rawan Alswailem, Fulwah Yahya Alqahtani, Fadilah Sfouq Aleanizy, Bahauddeen M. Alrfaei, Mohammad Badran, Qamraa Hamad Alqahtani, Hosam Gharib Abdelhady, Ibrahim Alsarra

Abstract

Recent evidence has implicated microRNA-219 (miR-219) in regulation of gene contributed in glioblastoma (GBM) pathogenesis. This study aimed to prepare miR-219 in chitosan (CS) nanoparticles (NPs), characterize and investigate their efficacy on human GBM cell line (U87 MG). NPs were prepared using ionic gelation method. The influence of process parameters on physicochemical characteristics of NPs was investigated. Apoptotic effect of miR-219 was examined on U87 MG cells. Formulated NPs showed particle size of 109 ± 2.18 nm, with poly dispersity index equal to 0.2 ± 0.05, and zeta potential of +20.5 ± 0.7 mV. Entrapment efficiency of miR-219 in loaded NP has reached 95%. The in vitro release study demonstrated sustained release pattern of miR-219 from CS-NPs. Gel retardation assay has confirmed the integrity of miR-219 after production process. The fabricated NPs reduced the survival of U87 MG cells to 78% after 24 h of post-transfection, and into 67.5% after 48 h. However, fibroblasts were not affected by the NPs, revealing their specificity for GBM cells. Given the tumour suppressing function of miR-219, and advantage of CS-NPs for gene delivery to the central nervous system, the presented NPs have a great potential for treatment of GBM.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · MicroRNA in disease regulation · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Drug sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia

Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Department of Cellular Therapy and Cancer Research, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health, Riyadh, Saudi Arabia

Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

College of Osteopathic Medicine, Sam Houston State University, Conroe, TX, USA

Funding

Researchers Supporting Project number · King Saud University

References (65)

Show source-provided references
1. 10.1001/archneurol.2010.510.1001/archneurol.2010.5 ↗
2. 10.1056/NEJMc08638010.1056/NEJMc086380 ↗
3. 10.4103/jnrp.jnrp_168_1710.4103/jnrp.jnrp_168_17 ↗
4. 10.1056/NEJMoa04333010.1056/NEJMoa043330 ↗
5. 10.1038/nature2300010.1038/nature23000 ↗
6. 10.1517/14728214.2012.67992910.1517/14728214.2012.679929 ↗
7. 10.18632/oncotarget.2347610.18632/oncotarget.23476 ↗
8. 10.1007/s11864-016-0418-010.1007/s11864-016-0418-0 ↗
9. Surgeons A. Brain tumors. Available from: https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Brain-Tumors.
10. Sciences F. Nerves: neural supporting cells. Available from: https://www.histology.leeds.ac.uk/tissue_types/nerves/Nerve_support_cell.php.
11. 10.1111/nan.1243210.1111/nan.12432 ↗
12. Howlader N Krapcho NA Miller M et al. SEER Cancer Statistics Review 1975. 2016. Available from: https://seer.cancer.gov/csr/1975_2016/.
13. 10.1016/j.critrevonc.2017.10.00310.1016/j.critrevonc.2017.10.003 ↗
14. 10.1155/2017/763908410.1155/2017/7639084 ↗
15. MicroRNA Targeted Cancer Therapy. 2014.
16. 10.1038/nature0738510.1038/nature07385 ↗
17. Hsu SD, Chu CH, Tsou AP, et al. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res. 2008;36(Database issue):D165–169.10.1093/nar/gkm1012 ↗
18. 10.1111/jlme.1213310.1111/jlme.12133 ↗
19. 10.3747/co.v13i6.10710.3747/co.v13i6.107 ↗
20. 10.1097/JNN.000000000000008810.1097/JNN.0000000000000088 ↗
21. 10.1371/journal.pone.006316410.1371/journal.pone.0063164 ↗
22. Jiang B, Li M, Ji F, et al. MicroRNA-219 exerts a tumor suppressive role in glioma via targeting Sal-like protein 4. Exp Ther Med. 2017;14(6):6213–6221.
23. 10.1007/s13277-015-3651-410.1007/s13277-015-3651-4 ↗
24. 10.1188/16.CJON.S1.2-810.1188/16.CJON.S1.2-8 ↗
25. 10.3174/ajnr.A501510.3174/ajnr.A5015 ↗
26. 10.1002/EXP.2021001010.1002/EXP.20210010 ↗
27. 10.1002/advs.20210200110.1002/advs.202102001 ↗
28. 10.1002/EXP.2021014910.1002/EXP.20210149 ↗
29. 10.1002/adma.20210477910.1002/adma.202104779 ↗
30. 10.1002/EXP.2021000810.1002/EXP.20210008 ↗
31. 10.4103/2152-7806.13213810.4103/2152-7806.132138 ↗
32. 10.1155/2012/42856510.1155/2012/428565 ↗
33. 10.1016/j.nic.2010.04.00610.1016/j.nic.2010.04.006 ↗
34. 10.1007/s11864-012-0208-210.1007/s11864-012-0208-2 ↗
35. 10.1080/0363904080252678910.1080/03639040802526789 ↗
36. 10.1016/j.carbpol.2015.11.04410.1016/j.carbpol.2015.11.044 ↗
37. 10.1155/2013/14632010.1155/2013/146320 ↗
38. 10.1016/j.jconrel.2016.02.03210.1016/j.jconrel.2016.02.032 ↗
39. 10.7717/peerj-cs.6710.7717/peerj-cs.67 ↗
40. 10.1007/s12094-016-1497-x10.1007/s12094-016-1497-x ↗
41. 10.1016/j.addr.2009.08.00410.1016/j.addr.2009.08.004 ↗
42. 10.1016/j.addr.2013.07.00510.1016/j.addr.2013.07.005 ↗
43. 10.3390/md1706038110.3390/md17060381 ↗
44. 10.1021/bm050912z10.1021/bm050912z ↗
45. 10.1016/0169-409X(95)00026-410.1016/0169-409X(95)00026-4 ↗
46. 10.1038/mt.2010.14310.1038/mt.2010.143 ↗
47. 10.1021/bm101482r10.1021/bm101482r ↗
48. 10.1016/j.ijpharm.2008.12.01210.1016/j.ijpharm.2008.12.012 ↗
49. 10.1016/S0169-409X(99)00033-210.1016/S0169-409X(99)00033-2 ↗
50. 10.3390/ph509099110.3390/ph5090991 ↗
51. 10.1016/j.biomaterials.2012.10.01310.1016/j.biomaterials.2012.10.013 ↗
52. 10.1016/j.colsurfb.2011.09.04210.1016/j.colsurfb.2011.09.042 ↗
53. 10.1038/s41598-018-23064-410.1038/s41598-018-23064-4 ↗
54. 10.1016/j.ijpharm.2013.07.02410.1016/j.ijpharm.2013.07.024 ↗
55. 10.1166/jnd.2013.102710.1166/jnd.2013.1027 ↗
56. Raja MA, Katas H, Jing Wen T. Stability, intracellular delivery, and release of siRNA from chitosan nanoparticles using different cross-linkers. PLoS One. 2015;10(6):e0128963.10.1371/journal.pone.0128963 ↗
57. 10.1016/j.carbpol.2012.03.01010.1016/j.carbpol.2012.03.010 ↗
58. 10.1016/j.jconrel.2006.07.02110.1016/j.jconrel.2006.07.021 ↗
59. 10.1016/j.carbpol.2013.02.01310.1016/j.carbpol.2013.02.013 ↗
60. 10.1016/j.jconrel.2004.08.01010.1016/j.jconrel.2004.08.010 ↗
61. 10.1080/02652049928906810.1080/026520499289068 ↗
62. 10.1002/jps.2214510.1002/jps.22145 ↗
63. 10.1016/j.addr.2009.06.00110.1016/j.addr.2009.06.001 ↗
64. 10.1016/j.coph.2006.04.00410.1016/j.coph.2006.04.004 ↗
65. 10.1038/nmat244210.1038/nmat2442 ↗